Answers are grounded in this paper and cite their sources.
Purpose: The aim of this study was to assess the efficacy of the nonsteroidal topical drug monotherapy on post-vitrectomy clinical recovery.Methods: Retrospective analysis of case notes and post-operative Optical Coherence Tomography (OCT) of 128 eye of 128 consecutive patients undergoing primary vitrectomy for primary rhegmatogenous retinal detachment (RRD) [n = 72], full thickness macular hole (MH) [n = 42], and epi-retinal membrane (ERM) [n = 15] at a single tertiary centre between 2011 and 2015.Results: Average LogMAR best-corrected visual acuity improved from 1.04 at baseline to 0.68 (95% CI 0.14 to -0.54, p = 0.001) at 20 weeks follow up for all indications.Average IOP did not change at follow up.Central retinal thickness (CRT) on OCT assessment did not change significantly in RRD patients postoperatively but reduced significantly in patients with MH from 389.81μm at baseline to 295.85μm at 20 weeks follow up compared to baseline (p< 0.0001).Patients with ERM had a significant reduction in CRT from 476.71μm at baseline to 388.86μm at 12 weeks (p < 0.05).Post-operative CMO was detectable on OCT in 3 of 72 patients with RRD, 1 of 43 patients with MH and 2 of 15 patients with ERM.Overall, 6 (4.7%) patients were found to have post-operative CMO.There were few complications including 6 (4.0%) patients with persistent post-operative CMO requiring treatment beyond 20 weeks follow-up.Conclusion: Topical ketorolac alone is an effective and safe post-operative therapy following vitrectomy surgery.
No takes yet. Share an insight, caveat, or question.
Shohista Saidkasimova (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: